Serveur d'exploration Covid

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Biological response modifiers and infectious diseases: Actual and potential therapeutic agents

Identifieur interne : 001298 ( Main/Exploration ); précédent : 001297; suivant : 001299

Biological response modifiers and infectious diseases: Actual and potential therapeutic agents

Auteurs : James J. Rusthoven [Canada]

Source :

RBID : ISTEX:3371F31F448BB6799E5DF28C7AC2139CDEA50284

English descriptors

Abstract

Abstract: Biological response modifiers (BRMs) are agents which can modify the immune response to cancer or invasion of the organism by infectious agents. An explosive appearance of new BRMs has resulted from the development of recombinant gene technology and the availability of monoclonal antibodies. Colony-stimulating factors first became available for the prevention of neutropenia but may also have a role in the treatment of infections. Interleukin-1 is being tested as a modular of hematopoiesis and may be useful as a helper factor for T- and B-cell function. Immunoglobulins are being used against viral and bacterial infections while interferons can prevent viral upper respiratory infections and suppress or irradicate some viral hepatitides. Other BRMs which show promise include chemical agents and traditional herbal medicines.

Url:
DOI: 10.1016/0924-8579(94)90050-7


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Biological response modifiers and infectious diseases: Actual and potential therapeutic agents</title>
<author>
<name sortKey="Rusthoven, James J" sort="Rusthoven, James J" uniqKey="Rusthoven J" first="James J." last="Rusthoven">James J. Rusthoven</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3371F31F448BB6799E5DF28C7AC2139CDEA50284</idno>
<date when="1994" year="1994">1994</date>
<idno type="doi">10.1016/0924-8579(94)90050-7</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-7JVG8HTS-C/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000785</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000785</idno>
<idno type="wicri:Area/Istex/Curation">000765</idno>
<idno type="wicri:Area/Istex/Checkpoint">000467</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000467</idno>
<idno type="wicri:doubleKey">0924-8579:1994:Rusthoven J:biological:response:modifiers</idno>
<idno type="wicri:Area/Main/Merge">001314</idno>
<idno type="wicri:Area/Main/Curation">001298</idno>
<idno type="wicri:Area/Main/Exploration">001298</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Biological response modifiers and infectious diseases: Actual and potential therapeutic agents</title>
<author>
<name sortKey="Rusthoven, James J" sort="Rusthoven, James J" uniqKey="Rusthoven J" first="James J." last="Rusthoven">James J. Rusthoven</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Hamilton Regional Cancer Centre, Ontario Cancer Foundation, Hamilton, Ont.</wicri:regionArea>
<wicri:noRegion>Ont.</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">International Journal of Antimicrobial Agents</title>
<title level="j" type="abbrev">ANTAGE</title>
<idno type="ISSN">0924-8579</idno>
<imprint>
<publisher>ELSEVIER</publisher>
<date type="published" when="1994">1994</date>
<biblScope unit="volume">3</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="223">223</biblScope>
<biblScope unit="page" to="243">243</biblScope>
</imprint>
<idno type="ISSN">0924-8579</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0924-8579</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Acad</term>
<term>Academic press</term>
<term>Alveolar macrophages</term>
<term>Animal models</term>
<term>Antibiotic</term>
<term>Antibody</term>
<term>Antibody titers</term>
<term>Antiidiotypic antibodies</term>
<term>Antimicrob agents chemother</term>
<term>Antiviral</term>
<term>Antiviral activity</term>
<term>Antiviral effect</term>
<term>Arch surg</term>
<term>Autologous bone marrow transplantation</term>
<term>Bacteremia</term>
<term>Bacterial infections</term>
<term>Biological activities</term>
<term>Biological properties</term>
<term>Biological response modifiers</term>
<term>Bone marrow transplantation</term>
<term>Cancer centre</term>
<term>Cancer immunol immunother</term>
<term>Child health</term>
<term>Chronic fatigue syndrome</term>
<term>Chronic hepatitis</term>
<term>Clin</term>
<term>Clin immunol immunopathol</term>
<term>Clin oncol</term>
<term>Clinical benefit</term>
<term>Clinical testing</term>
<term>Clinical trials</term>
<term>Coli</term>
<term>Complete remission</term>
<term>Crit care</term>
<term>Csfs</term>
<term>Cyclic neutropenia</term>
<term>Cystic fibrosis</term>
<term>Cytokine</term>
<term>Cytomegalovirus</term>
<term>Cytomegalovirus infection</term>
<term>Cytomegalovirus pneumonia</term>
<term>Different subsets</term>
<term>Dinarello</term>
<term>Diphtheria toxin</term>
<term>Dos</term>
<term>Endogenous</term>
<term>Endogenous mediators</term>
<term>Endogenous pyrogen</term>
<term>Endotoxin</term>
<term>Engl</term>
<term>Envelope protein</term>
<term>Escherichia coli</term>
<term>Febrile patients</term>
<term>Gene expression</term>
<term>Gramnegative bacteremia</term>
<term>Granulocyte</term>
<term>Granulocyte colonystimulating factor</term>
<term>Granulocyte factor</term>
<term>Granulocytemacrophage factor</term>
<term>Helper factor</term>
<term>Hematopoietic</term>
<term>Hematopoietic progenitors</term>
<term>Hepatitis</term>
<term>High type</term>
<term>Human development</term>
<term>Human immunodeficiency virus</term>
<term>Human leukocyte interferon</term>
<term>Idiopathic thrombocytopenic purpura</term>
<term>Immune</term>
<term>Immune globulin</term>
<term>Immune response</term>
<term>Immune responses</term>
<term>Immune system</term>
<term>Immunodeficiency</term>
<term>Immunodeficiency syndrome</term>
<term>Immunodeficiency virus</term>
<term>Immunodeficiency virus infection</term>
<term>Immunoglobulin</term>
<term>Immunol</term>
<term>Infection</term>
<term>Infection dissemination</term>
<term>Infection prevention</term>
<term>Infection treatment</term>
<term>Infectious agents</term>
<term>Infectious diseases</term>
<term>Inflammation</term>
<term>Inflammatory disease</term>
<term>Inflammatory response</term>
<term>Inhibitor</term>
<term>Initial evaluation</term>
<term>Interferon</term>
<term>Interleukin</term>
<term>Intern</term>
<term>Intravenous</term>
<term>Intravenous gammaglobulin</term>
<term>Intravenous gammaglobulin treatment</term>
<term>Intravenous immunoglobulin</term>
<term>Intravenous immunoglobulin therapy</term>
<term>Intravenous immunoglobulins</term>
<term>Ivig</term>
<term>Kawasaki syndrome</term>
<term>Lancet</term>
<term>Local environment</term>
<term>Macrophage</term>
<term>Marrow transplantation</term>
<term>Mediator</term>
<term>Monoclonal</term>
<term>Monoclonal antibodies</term>
<term>Monoclonal antibody</term>
<term>Multiple organ failure</term>
<term>Multiple systems organ failure</term>
<term>National institute</term>
<term>Natl</term>
<term>Necrosis</term>
<term>Neonatal</term>
<term>Neonatal rats</term>
<term>Neonatal sepsis</term>
<term>Network theory</term>
<term>Neutropenia</term>
<term>Neutrophil</term>
<term>Neutrophil counts</term>
<term>Neutrophil function</term>
<term>Neutrophil recovery</term>
<term>Other agents</term>
<term>Other studies</term>
<term>Pediatr</term>
<term>Placebo</term>
<term>Proc</term>
<term>Proc natl acad</term>
<term>Progenitor</term>
<term>Prophylactic</term>
<term>Prophylaxis</term>
<term>Pseudomonas</term>
<term>Pseudomonas bacteremia</term>
<term>Pseudomonas sepsis</term>
<term>Pulmonary exacerbations</term>
<term>Pulmonary host defences</term>
<term>Pulmonary infection</term>
<term>Rabies virus</term>
<term>Randomized</term>
<term>Randomized trial</term>
<term>Randomized trials</term>
<term>Recent randomized trials</term>
<term>Receptor</term>
<term>Recombinant</term>
<term>Recombinant interferon</term>
<term>Remission</term>
<term>Respiratory illness</term>
<term>Rhinovirus</term>
<term>Rhinovirus colds</term>
<term>Rhinovirus infections</term>
<term>Same model</term>
<term>Sepsis</term>
<term>Septic shock</term>
<term>Seronegative recipients</term>
<term>Serum levels</term>
<term>Side effects</term>
<term>Significant reduction</term>
<term>Small cell lung cancer</term>
<term>Splenectomized mice</term>
<term>Standard treatment</term>
<term>Stress response</term>
<term>Such agents</term>
<term>Such vaccines</term>
<term>Supportive therapy</term>
<term>Surgical patients</term>
<term>Symptomatic improvement</term>
<term>Syndrome</term>
<term>Thermal injury</term>
<term>Traditional chinese medicines</term>
<term>Transplantation</term>
<term>Tumour</term>
<term>Tumour necrosis factor</term>
<term>Uncontrolled studies</term>
<term>Vaccine</term>
<term>Vascular endothelium</term>
<term>Viral</term>
<term>Viral hepatitis</term>
<term>Viral infections</term>
<term>Virus infection</term>
<term>Zidovudine</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Biological response modifiers (BRMs) are agents which can modify the immune response to cancer or invasion of the organism by infectious agents. An explosive appearance of new BRMs has resulted from the development of recombinant gene technology and the availability of monoclonal antibodies. Colony-stimulating factors first became available for the prevention of neutropenia but may also have a role in the treatment of infections. Interleukin-1 is being tested as a modular of hematopoiesis and may be useful as a helper factor for T- and B-cell function. Immunoglobulins are being used against viral and bacterial infections while interferons can prevent viral upper respiratory infections and suppress or irradicate some viral hepatitides. Other BRMs which show promise include chemical agents and traditional herbal medicines.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
</list>
<tree>
<country name="Canada">
<noRegion>
<name sortKey="Rusthoven, James J" sort="Rusthoven, James J" uniqKey="Rusthoven J" first="James J." last="Rusthoven">James J. Rusthoven</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001298 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001298 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    CovidV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:3371F31F448BB6799E5DF28C7AC2139CDEA50284
   |texte=   Biological response modifiers and infectious diseases: Actual and potential therapeutic agents
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Fri Mar 27 18:14:15 2020. Site generation: Sun Jan 31 15:15:08 2021